Frances L. Johnson

3.6k total citations · 2 hit papers
45 papers, 2.5k citations indexed

About

Frances L. Johnson is a scholar working on Surgery, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Frances L. Johnson has authored 45 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 12 papers in Biomedical Engineering and 11 papers in Molecular Biology. Recurrent topics in Frances L. Johnson's work include Mechanical Circulatory Support Devices (11 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Cardiac Structural Anomalies and Repair (9 papers). Frances L. Johnson is often cited by papers focused on Mechanical Circulatory Support Devices (11 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Cardiac Structural Anomalies and Repair (9 papers). Frances L. Johnson collaborates with scholars based in United States, South Korea and China. Frances L. Johnson's co-authors include Amy J. Wagers, Douglas E. Wright, Irving L. Weissman, Philip S. Tsao, Anjali Pathak, Shuichiro Kaji, Christopher Heeschen, Michael Weis, James J. Jang and John P. Cooke and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Frances L. Johnson

43 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Physiological Migration of Hematopoietic Stem and Progenitor Cells

2001 717 citations Frances L. Johnson et al. profile →
Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis

2001 647 citations Christopher Heeschen, James J. Jang et al. Nature Medicine profile →

Peers

Countries citing papers authored by Frances L. Johnson

Since Specialization

Citations

This map shows the geographic impact of Frances L. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frances L. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frances L. Johnson more than expected).

Fields of papers citing papers by Frances L. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frances L. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frances L. Johnson. The network helps show where Frances L. Johnson may publish in the future.

Co-authorship network of co-authors of Frances L. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Frances L. Johnson. A scholar is included among the top collaborators of Frances L. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frances L. Johnson. Frances L. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I/IIa of [²¹²Pb]VMT01 targeted a-particle therapy for unresectable or metastatic melanoma. 2024 ·Journal of Clinical Oncology ·Zachary S. Morris, Markus Puhlmann, Frances L. Johnson, (unknown), Steve Y. Cho	4
2	Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics 2023 ·Pharmaceutics ·Mengshi Li, Nicholas J. Baumhover, Dijie Liu, (unknown), Fréderic Boschetti, (unknown), (unknown), Cong Dai, (unknown), (unknown), (unknown), (unknown), Moustafa T. Gabr, F. Christopher Pigge, Frances L. Johnson, Michael K. Schultz	29
3	Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Mengshi Li, Dijie Liu, Nicholas J. Baumhover, (unknown), (unknown), Prerna Rastogi, F. Christopher Pigge, Yusuf Menda, Frances L. Johnson, Michael K. Schultz	14
4	Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·Mengshi Li, (unknown), Dijie Liu, Stephen A. Graves, (unknown), (unknown), (unknown), Prerna Rastogi, (unknown), (unknown), Robert M. Weiss, (unknown), Frances L. Johnson, Michael K. Schultz, Diana Zepeda‐Orozco	3
5	Dosimetry of [212Pb]VMT01, a MC1R-Targeted Alpha Therapeutic Compound, and Effect of Free 208Tl on Tissue Absorbed Doses 2022 ·Molecules ·Kelly Davis Orcutt, Kelly E. Henry, (unknown), (unknown), (unknown), (unknown), Vijay Gottumukkala, Derek D. Cissell, (unknown), Amira I. Hussein, (unknown), Mengshi Li, Frances L. Johnson, Michael K. Schultz	7
6	203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer 2020 ·Current Medicinal Chemistry ·Mengshi Li, (unknown), (unknown), Daniel R. McAlister, (unknown), (unknown), Stephen A. Graves, Roy Copping, Saed Mirzadeh, Brian E. Zimmerman, Roy H. Larsen, Frances L. Johnson, Michael K. Schultz	37
7	Usefulness of Cardiac Resynchronization Therapy in Patients With Continuous Flow Left Ventricular Assist Devices 2018 ·The American Journal of Cardiology ·(unknown), Frances L. Johnson, (unknown), KellyAnn Light-McGroary, Chakradhari Inampudi, (unknown), (unknown), Carol Johnson, (unknown), (unknown), (unknown), (unknown), Michael Giudici	10
8	Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer 2017 ·Applied Radiation and Isotopes ·Mengshi Li, Xiuli Zhang, Thomas P. Quinn, (unknown), Dijie Liu, (unknown), Brian E. Zimmerman, Daniel R. McAlister, (unknown), Yusuf Menda, Saed Mirzadeh, Roy Copping, Frances L. Johnson, Michael K. Schultz	36
9	INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure 2016 ·Circulation Heart Failure ·Garrick C. Stewart, M. Kittleson, Parag C. Patel, Jennifer Cowger, Chetan B. Patel, Maria Mountis, Frances L. Johnson, Maya Guglin, J. Eduardo Rame, Jeffrey J. Teuteberg, Lynne W. Stevenson	49
10	Molecular Determinants of Calpain-dependent Cleavage of Junctophilin-2 Protein in Cardiomyocytes 2015 ·Journal of Biological Chemistry ·Ang Guo, Duane D. Hall, Caimei Zhang, Tianqing Peng, Jordan D. Miller, William Kutschke, Chad E. Grueter, Frances L. Johnson, Richard Z. Lin, Long‐Sheng Song	58
11	In Vivo Tracking of Streptococcal Infections of Subcutaneous Origin in a Murine Model 2015 ·Molecular Imaging and Biology ·Richard W. Davis, (unknown), Frances L. Johnson, Matthias Nahrendorf, Paul Bock, Tiffany A. Peterson, Peter Panizzi	2
12	Microtubule-Mediated Defects in Junctophilin-2 Trafficking Contribute to Myocyte Transverse-Tubule Remodeling and Ca ²⁺ Handling Dysfunction in Heart Failure 2014 ·Circulation ·Caimei Zhang, Biyi Chen, Ang Guo, (unknown), Jordan D. Miller, Shan Gao, Can Yuan, William Kutschke, Kathy Zimmerman, Robert M. Weiss, Xander H.T. Wehrens, Hong Jiang, Frances L. Johnson, Luis F. Santana, Mark E. Anderson, Long‐Sheng Song	107
13	Abstract 8490: End Stage Heart Failure: Are We Missing Patients Who May Benefit from Left Ventricular Assist Device Support? 2011 ·Circulation ·Jennifer Cowger, M. Kittleson, Chetan B. Patel, (unknown), J. Eduardo Rame, Maria Mountis, (unknown), Frances L. Johnson, Jeffrey J. Teuteberg, Maya Guglin, Keith D. Aaronson	1
14	The Impact of Prolonged Rotary Ventricular Assist Device Support upon Ventricular Geometry and Flow Kinetics 2010 ·Journal of the American Society of Echocardiography ·Robert M. Weiss, Richard E. Kerber, (unknown), (unknown), B. Cabuay, Ashrith Guha, Wassef Karrowni, James E. Davis, Frances L. Johnson	8
15	Robust gene expression with amplified RNA from biopsy-sized human heart tissue 2006 ·Journal of Molecular and Cellular Cardiology ·Brian R. Barrows, Agnes M. Azimzadeh, Stacey L. McCulle, (unknown), (unknown), Nicholas P. Ambulos, Jing Yin, Hegang Chen, C. William Balke, Christine S. Moravec, Richard N. Pierson, Stephen S. Gottlieb, Meredith Bond, Frances L. Johnson	7
16	Brain Injury and Ventricular Dysfunction: Insights Into Reversible Heart Failure 2005 ·Congestive Heart Failure ·(unknown), Frances L. Johnson, Mandeep R. Mehra	13
17	Dependency-Directed Reconsideration 2004 ·eScholarship (California Digital Library) ·Frances L. Johnson, Stuart C. Shapiro	3
18	The Embryonic Angiogenic Factor Del1 Accelerates Tumor Growth by Enhancing Vascular Formation 2002 ·Microvascular Research ·Yoshikazu Aoka, Frances L. Johnson, Kalyani Penta, Ken-ichi Hirata, Chiaki Hidai, Randall C. Schatzman, Judith A. Varner, Thomas Quertermous	69
19	Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis breakdown → 2001 ·Nature Medicine ·Christopher Heeschen, James J. Jang, Michael Weis, Anjali Pathak, Shuichiro Kaji, (unknown), Philip S. Tsao, Frances L. Johnson, John P. Cooke	647
20	Formalizing a Deductively Open Belief Space 2000 ·Frances L. Johnson, Stuart C. Shapiro	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact